Stock listing
CLNN Stock Price, News, Filings & Events — Clene Inc.
Selected listing: CLNN · NASDAQ · USD · US
This page tracks Clene Inc.'s CLNN:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following CLNN:NASDAQ. CLNN:NASDAQ is the stock-level entry point for investors researching Clene Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Clene Inc. is a public company traded under the ticker CLNN in the American market, with a market capitalization of approximately $75.6 million. The company focuses on developing innovative therapies for neurodegenerative diseases. Clene aims to improve patient outcomes through its unique approach to treatment.

- Ticker
- CLNN:NASDAQ
- Asset type
- Stock
- Market cap
- $45.9M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- NASDAQ
- Currency
- USD
Clene Inc. CLNN:NASDAQ stock context
This page tracks Clene Inc.'s CLNN:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following CLNN:NASDAQ. CLNN:NASDAQ is the stock-level entry point for investors researching Clene Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Clene Inc. is a public company traded under the ticker CLNN in the American market, with a market capitalization of approximately $75.6 million. The company focuses on developing innovative therapies for neurodegenerative diseases. Clene aims to improve patient outcomes through its unique approach to treatment.
Latest news from Clene Inc.
Clene to Present at Upcoming September Investor Conferences
September 3, 2026
Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights
August 14, 2026
Clene Announces Biomarker Analyses To Be Included in NDA Submission Supporting ALS Accelerated Approval
August 10, 2026
Clene to Present at The Canaccord 46th Annual Growth Conference
July 29, 2026
Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cel...
May 26, 2026
Research Clene Inc.
Clene Inc. investor report
Review AI stock analysis and investor report context for CLNN:NASDAQ.
Clene Inc. company profile
View the public company page for Clene Inc. on 6ix.
Clene Inc. news
Read company news and market updates connected to Clene Inc..
Clene Inc. investor events
Find investor webinars, events, and replay context for Clene Inc..
Alternate listings
CLNN:BOATS
US · USD
Alternate listing for Clene Inc.; the primary context on this page is CLNN:NASDAQ.
84C0:FWB
DE · EUR
Alternate listing for Clene Inc.; the primary context on this page is CLNN:NASDAQ.
84C0:TRADEGATE
DE · EUR
Alternate listing for Clene Inc.; the primary context on this page is CLNN:NASDAQ.